Overview

Hemato Oncology Testing Market Introduction

Hemato Oncology Testing Market is estimated to value over USD 5.2 billion by 2029 end and register a CAGR of over 14.6% during the forecast period 2020 to 2029. 

The type of product and service, the global hemato oncology market is bifurcated into services segment and assay kits segment.
Based on the type of cancer, the market is categorised as leukaemia, acute myeloid leukaemia, acute lymphocytic leukaemia, lymphoma, non-hodgkin lymphoma, hodgkin lymphoma and others. As leukaemia patients require continuous monitoring and considering the ever-increasing number of leukaemia cases worldwide, this segment is anticipated to dominate the market during the forecast period.

Technology-wise, the market is bifurcated into PCR, NGS, IHC, Cytogenetics and others. PCR technology segment is anticipated to showcase a significant market growth in 2019 owing to the ease of use and availability of assay kits.

Global Hemato Testing Oncology Market Regional Insight

The market is geographically segmented into North America, Europe, Asia Pacific and rest of the world. North America is expected to dominate the global market during the forecast period owing to a growing awareness of advanced treatment theories, a strong presence of key market players in the region and availability of reimbursement for hemato oncology testing products.

Major Key Players in Hemato Oncology Testing  Market :
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Illumine Inc.
• Molecular MD
• Invivoscribe Inc.
• Qiagen N.V.
• Bio-Rad Laboratories, Inc.
• Archerdx, Inc.
• Arup Laboratories Inc.
• Asuragen, Inc.
• Adaptive Biotechnologies.
• Cepheid
• Entrogen, Inc.

Hemato Testing Oncology Market Segmentation:

By Region
•    North America
•    Europe
•    Asia Pacific
•    Rest of the World

By Product & Service Type 
• Services
• Assay Kits

By Cancer Type 
• Leukemia
   o Acute Myeloid Leukemia (AML)
   o Acute Lymphocytic Leukemia (ALL)
   o Chronic Lymphocytic Leukemia
   o Chronic Myeloid Leukemia
• Lymphoma
   o Non-Hodgkin Lymphoma
   o Hodgkin Lymphoma
• Myeloproliferative Neoplasms
   o Polycythemia vera (PV)
   o Essential thrombocythemia (ET)
   o Myelofibrosis (MF)
• Other Cancers

By Technology
• PCR
• NGS
• IHC
• Cytogenetics
• Others

By End User
• Clinical laboratories
• Hospitals
• Academic & Research Institutes
• Other End Users (CROs, Pharmaceutical & Biotechnology Companies)

Competitive Landscape:
•    Tier 1 players- established companies in the market with a major market share  
•    Tier 2 players 
•    Emerging players which are growing rapidly 
•    New Entrants  

FutureWise Key Takeaways:
•    Growth prospects
•    SWOT analysis 
•    Key trends 
•    Key data-points affecting market growth 

Objectives of the Study:
•   To provide with an exhaustive analysis on the Hemato Oncology Testing Market By Product & Service Type, By Cancer Type, By Technology, By End User and By           Region.
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific and rest of the world
•    To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1 Objectives of the Study 
   1.2 Market Definition 
   1.3 Market Scope 
       1.3.1 Years Considered for the Study
       1.3.2 Market Covered
   1.4 Currency 
   1.5 Limitations 
   1.6 Stakeholders 

2. Research Cancer Typeology 
    2.1 Research Data 
        2.1.1 Secondary Data
              2.1.1.1 Key Data from Secondary Sources
        2.1.2 Primary Data
              2.1.2.1 Key Data from Primary Sources
    2.2 Market Size Estimation 
    2.3 Market Breakdown and Data Triangulation 
    2.4 Assumptions for the Study  

3. Executive Summary
   3.1 Market Outlook
   3.2 Segment Outlook
   3.3 Competitive Insights

4. Global Hemato Oncology Testing Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Hemato Oncology Testing Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Hemato Oncology Testing Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Global Hemato Oncology Testing Market, By Product & Service Type Historical Analysis and Forecast 2020-2027 (USD Million)
        7.1. Services
        7.2. Assay Kits

8. Global Hemato Oncology Testing Market, By Cancer Type Historical Analysis and Forecast 2020-2027 (USD Million)  
   8.1. Leukemia
        8.1.1. Acute Myeloid Leukemia (AML)
        8.1.2. Acute Lymphocytic Leukemia (ALL)
        8.1.3. Chronic Lymphocytic Leukemia
        8.1.4. Chronic Myeloid Leukemia
   8.2. Lymphoma
        8.2.1. Non-Hodgkin Lymphoma
        8.2.2. Hodgkin Lymphoma
   8.3. Myeloproliferative Neoplasms
        8.3.1. Polycythemia vera (PV)
        8.3.2. Essential thrombocythemia (ET)
        8.3.3. Myelofibrosis (MF)
   8.4. Other Cancers

9. Global Hemato Oncology Testing Market, By Technology Historical Analysis and Forecast 2020-2027 (USD Million)  
   9.1. PCR
   9.2. NGS
   9.3. IHC
   9.4. Cytogenetics
   9.5. Others

10. Global Hemato Oncology Testing Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)  
    10.1. Clinical laboratories
    10.2. Hospitals
    10.3. Academic & Research Institutes
    10.4. Diagnostic Laboratories
    10.5. Other End Users (CROs, Pharmaceutical & Biotechnology Companies)

11. North America Hemato Oncology Testing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   11.1. Introduction
   11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
        11.2.1. U.S.A
        11.2.2. Canada
        11.2.3. Mexico
   11.3. Market Size (USD Million) Forecast for North America 2020-2027

12. Latin America Hemato Oncology Testing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          12.2.1. Brazil
          12.2.2. Venezuela
          12.2.3. Argentina
          12.2.4. Rest of Latin America
    12.3. Market Size (USD Million) Forecast for Latin America 2020-2027

13. Europe Hemato Oncology Testing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          13.2.1. Germany
          13.2.2. U.K         
          13.2.3. France
          13.2.4. Italy
          13.2.5. Spain
          13.2.6. Russia
          13.2.7. Poland
          13.2.8. Rest of Europe
    13.3. Market Size (USD Million) Forecast for Europe 2020-2027

14. Asia Pacific Hemato Oncology Testing Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          14.2.1. Japan
          14.2.2. China
          14.2.3. India
          14.2.4. Australia and New Zealand
          14.2.5. ASEAN
          14.2.6. Rest of Asia Pacific
    14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027  

15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          15.2.1. Saudi Arabia
          15.2.2. UAE
          15.2.3. South Africa
          15.2.4. Egypt
    15.3. Market Size (USD Million) Forecast for MEA 2020-2027

16. Market Share Analysis and Competitive Landscape   
    16.1. Global Landscape - Key Players, Revenue and Presence
    16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    16.3. Global Emerging Companies
    16.4.  North America - Market Share Analysis and Key Regional Players
    16.5.  Europe - Market Share Analysis and Key Regional Players
    16.6.  Asia Pacific - Market Share Analysis and Key Regional Players
    16.7.  Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product & Service Types Offered and Financial Layouts)
  17.1. F. Hoffmann-La Roche Ltd.
          17.1.1. Company Overview
          17.1.2. Mode of operation Portfolio
          17.1.3. SWOT Analysis
          17.1.4. Financial Overview
          17.1.5. Strategic Overview
  17.2. Abbott Laboratories
          17.2.1. Company Overview
          17.2.2. Mode of operation Portfolio
          17.2.3. SWOT Analysis
          17.2.4. Financial Overview
          17.2.5. Strategic Overview 
  17.3. Thermo Fisher Scientific Inc.
          17.3.1. Company Overview
          17.3.2. Mode of operation Portfolio
          17.3.3. SWOT Analysis
          17.3.4. Financial Overview
          17.3.5. Strategic Overview
  17.4. Illumine Inc.
          17.4.1. Company Overview
          17.4.2. Mode of operation Portfolio
          17.4.3. SWOT Analysis
          17.4.4. Financial Overview
          17.4.5. Strategic Overview
  17.5. Molecular MD
          17.5.1. Company Overview
          17.5.2. Mode of operation Portfolio
          17.5.3. SWOT Analysis
          17.5.4. Financial Overview
          17.5.5. Strategic Overview          
  17.6. Invivoscribe Inc.
          17.6.1. Company Overview
          17.6.2. Mode of operation Portfolio
          17.6.3. SWOT Analysis
          17.6.4. Financial Overview
          17.6.5. Strategic Overview      
  17.7. Qiagen N.V.
          17.7.1. Company Overview
          17.7.2. Product & Service Type Portfolio
          17.7.3. SWOT Analysis
          17.7.4. Financial Overview
          17.7.5. Strategic Overview
  17.8. Bio-Rad Laboratories, Inc.
          17.8.1. Company Overview
          17.8.2. Product & Service Type Portfolio
          17.8.3. SWOT Analysis
          17.8.4. Financial Overview
          17.8.5. Strategic Overview 
  17.9. Archerdx, Inc.
          17.9.1. Company Overview
          17.9.2. Product & Service Type Portfolio
          17.9.3. SWOT Analysis
          17.9.4. Financial Overview
          17.9.5. Strategic Overview 
 17.10.Arup Laboratories Inc..
          17.10.1. Company Overview
          17.10.2. Product & Service Type Portfolio
          17.10.3. SWOT Analysis
          17.10.4. Financial Overview
          17.10.5. Strategic Overview
 17.11.Asuragen, Inc.
          17.11.1. Company Overview
          17.11.2. Technology Portfolio
          17.11.3. SWOT Analysis
          17.11.4. Financial Overview
          17.11.5. Strategic Overview 
    17.12.Adaptive Biotechnologies.
          17.12.1. Company Overview
          17.12.2. Technology Portfolio
          17.12.3. SWOT Analysis
          17.12.4. Financial Overview
          17.12.5. Strategic Overview 
 17.13.Cepheid
          17.13.1. Company Overview
          17.13.2. Technology Portfolio
          17.13.3. SWOT Analysis
          17.13.4. Financial Overview
          17.13.5. Strategic Overview 
   17.14.Entrogen, Inc.
          17.14.1. Company Overview
          17.14.2. Technology Portfolio
          17.14.3. SWOT Analysis
          17.14.4. Financial Overview
          17.14.5. Strategic Overview  

18. Pre and Post COVID-19 Impact
    18.1. Positive influence on the healthcare industry
    18.2. The financial disruption of the manufacturing sector
    18.3. Impact of COVID-19 on emerging companies
    18.4. Significant mandates in the healthcare regulations initiated by administrations
    18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client
 

Tables

Figures